Page last updated: 2024-10-28

hydralazine and Airflow Obstruction, Chronic

hydralazine has been researched along with Airflow Obstruction, Chronic in 1 studies

Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.

Research Excerpts

ExcerptRelevanceReference
"Approximately 1 in 5 hospitalized COPD patients are readmitted within 30 days of discharge."2.82Evaluation of Chronic Obstructive Pulmonary Disease (COPD) and reduced ejection fraction heart failure (HFrEF) discharge medication prescribing: Is drug therapy concordant with national guidelines associated with a reduction in 30-day readmissions? ( Bowlin, B; Finch, C; Hartmann, J; Reedus, J; Richardson, A; Sands, CW; Self, T; Tolley, E, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Richardson, A1
Tolley, E1
Hartmann, J1
Reedus, J1
Bowlin, B1
Finch, C1
Sands, CW1
Self, T1

Trials

1 trial available for hydralazine and Airflow Obstruction, Chronic

ArticleYear
Evaluation of Chronic Obstructive Pulmonary Disease (COPD) and reduced ejection fraction heart failure (HFrEF) discharge medication prescribing: Is drug therapy concordant with national guidelines associated with a reduction in 30-day readmissions?
    Respiratory medicine, 2016, Volume: 119

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I

2016